Show simple item record

dc.contributor.authorKapczynski, Amy
dc.contributor.authorBrown, Nathan
dc.contributor.authorBhargava, Raj
dc.date.accessioned2024-03-27T15:44:25Z
dc.date.available2024-03-27T15:44:25Z
dc.date.issued2023
dc.identifier.citationBhargava, Raj, et al. “The Constitutionality of Medicare Drug-Price Negotiation under the Takings Clause.” Journal of Law, Medicine & Ethics, vol. 51, no. 4, Winter 2023, pp. 961–71.en_US
dc.identifier.urihttp://hdl.handle.net/20.500.13051/18407
dc.description.abstractIn recent months, pharmaceutical manufacturers have brought legal challenges to a provision of the 2022 Inflation Reduction Act (IRA) empowering the federal government to negotiate the prices Medicare pays for certain prescription medications. One key argument made in these filings is that price negotiation is a "taking" of property and violates the Takings Clause of the US Constitution. Through original case law and health policy analysis, we show that government price negotiation and even price regulation of goods and services, including patented goods, are constitutional under the Takings Clause. Finding that the IRA violates the Takings Clause would radically upend settled constitutional law and jeopardize the US's most important state and federal health care programs.en_US
dc.publisherJournal of Law, Medicine & Ethicsen_US
dc.subjectInflation Reduction Act; Medicare; Patents; Price Negotiation; Takings Clauseen_US
dc.titleThe Constitutionality of Medicare Drug-Price Negotiation under the Takings Clauseen_US
rioxxterms.versionNAen_US
rioxxterms.typeJournal Article/Reviewen_US
refterms.dateFOA2024-03-27T15:44:26Z
refterms.dateFirstOnline2024


Files in this item

Thumbnail
Name:
The Constitutionality of Medicare ...
Size:
202.8Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record